OncoSec Medical to Present at Two Conferences in New York City in April
March 31 2014 - 6:03AM
Business Wire
Company to Present at 13th Annual Needham
Healthcare Conference and HemOnc Today Melanoma and Cutaneous
Malignancies Meeting
OncoSec Medical Inc. (OTCQB: ONCS), a company developing
its ImmunoPulse DNA-based immunotherapy to treat solid tumors, will
present at the 13th Annual Needham Healthcare Conference and the
HemOnc Today Melanoma and Cutaneous Malignancies Meeting in
April.
Punit Dhillon, President and CEO, will present a corporate
overview of the company at the 13th Annual Needham Healthcare
Conference at the Westin Grand Central Hotel in New York City on
Tuesday, April 8th, at 11:20 a.m. ET. That presentation will be
webcast live, and available at the following link:
http://wsw.com/webcast/needham65/oncs
OncoSec recommends registering at least 10 minutes prior to the
start of the presentation to ensure timely access. After the
presentation, an archived version of the webcast will be available
for 90 days in the “Events” section of the OncoSec web page at
http://www.oncosec.com
Additionally, Adil Daud, M.D., Principal Investigator for
OncoSec’s Phase 2 melanoma study, will discuss developing
intralesional therapies at the HemOnc Today Melanoma and Cutaneous
Malignancies Meeting at the Sheraton New York Times Square Hotel,
in New York City on Friday, April 11th, at 2:40 p.m. ET.
HemOnc Today will bring together more than 25 renowned speakers
and 200 colleagues to participate in an intimate and interactive
meeting during the weekend of April 11-12, 2014, in New York City,
New York. The dynamic meeting program is designed to encourage open
communications and exchange of ideas among leading hematologists,
oncologists, dermatologists, researchers, physician assistants,
nurses, and students. For more information, please visit:
http://www.healio.com/meeting/hemonctodaymelanoma/home
About OncoSec Medical Inc.
OncoSec Medical Inc. is a biopharmaceutical company developing
its ImmunoPulse immunotherapy to treat solid tumors. OncoSec’s core
technology leverages a proprietary electroporation platform to
enhance the local delivery and uptake of IL-12 and other
DNA-based immune-modulating agents. Clinical studies of ImmunoPulse
have demonstrated an acceptable safety profile and preliminary
evidence of anti-tumor activity in the treatment of various skin
cancers, as well as the potential to initiate a systemic immune
response without the systemic toxicities associated with other
treatments. OncoSec’s clinical programs currently include three
Phase 2 trials in patients with metastatic melanoma, Merkel cell
carcinoma and cutaneous T-cell lymphoma
(http://clinicaltrials.gov/ct2/results?term=oncosec&Search=Search).
As the company continues to evaluate ImmunoPulse in these
indications, it is also investigating additional indications and
combination therapy approaches. For more information, please
visit www.oncosec.com.
This press release contains forward-looking statements within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995. Any statements in this release that are not historical facts
may be considered such “forward-looking statements.”
Forward-looking statements are based on management’s current
preliminary expectations and are subject to risks and
uncertainties, which may cause our results to differ materially and
adversely from the statements contained herein. Some of the
potential risks and uncertainties that could cause actual results
to differ from those predicted include our ability to raise
additional funding, our ability to acquire, develop or
commercialize new products, uncertainties inherent in pre-clinical
studies and clinical trials, unexpected new data, safety and
technical issues, competition, and market conditions. These and
additional risks and uncertainties are more fully described in
OncoSec Medical’s filings with the Securities and Exchange
Commission. Undue reliance should not be placed on forward-looking
statements, which speak only as of the date they are made. OncoSec
Medical disclaims any obligation to update any forward-looking
statements to reflect new information, events or circumstances
after the date they are made, or to reflect the occurrence of
unanticipated events.
Investor Relations:OncoSec Medical Inc.Veronica Vallejo,
CFO855-662-6732investors@oncosec.com
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Mar 2024 to Apr 2024
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Apr 2023 to Apr 2024